Sequential chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone doses was administered to 57 adult patients with acute lymphoblastic leukemia (ALL). Complete remission (CR) was achieved in 51 (89%, 95% confidence intervals, [CI] 78-96%). Among patients achieving CR, 62% were in CR after one sequence of chemotherapy, 23% after two sequences, and 5% after three sequences. Six patients (11%) had resistant disease. All patients experienced profound myelosuppression. Median time to recovery of neutrophils >0.5 x 10(9)/l was 22 days (range: 5-89 days), and of platelets >100 x 10(9)/l 21 days (range: 0-45 days). Nonhematologic WHO grade 3 or more side effects consisted predominantly of hyperbilirubinemia (7%), mucositis (5%), nausea and vomiting (2%), and cutaneous toxicity (1%). Severe infectious complications occurred in only 14% of cases. One patient (2%, 95% CI 0-9%) died of therapy-related toxicity while in early CR. We concluded that sequential use of prednisone seemed at least as effective as continuous administration at the expense of a few adverse side effects.
Bassan R, Battista R, D'Emilio A, Viero P, Dragone P, Dini E, Barbui T (1991) Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia. Eur J Cancer 27:441–447
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. Br J Haematol 33:451–458
Bezwoda WR, Seymour L, Ariad S, McPhail P (1991) Acute lymphoblastic leukaemia in adults. Prognostic factors and 10-year treatment results. Leukemia Lymphoma 5:347–355
Blacklock HA, Matthews JR, Buchanan JG, Ockelford PA, Hill RS (1981) Improved survival from acute lymphoblastic leukemia in adolescents and adults. Cancer 48:1931–1938
Boggs DR, Wintrobe MM, Cartwright GE (1962) The acute leukemias. Medicine 41:163–167
Champlin R, Gale RP (1989) Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood 73:2051–2066
Cuttner J, Mick R, Budman DR, Mayer RJ, Lee EJ, Henderson ES, Weiss RB, Paciucci PA, Sobol R, Davey F, Bloomfiel C, Schiffer C (1991) Phase-III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia 5:425–431
Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Bloom J, Leone LA, Haurani F, Kyle R, Hutchison JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507–523
Fiere D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP, Varet B, Broustet A, Cahn JY, Rigal-Huguet F, Witz F, Michaux JL, Michallet M, Reiffers J for the French Group on Therapy for Adult Acute Lymphoblastic Leukemia (1993) Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 11:1990–2001
GIMENA Cooperative Group (1989) GIMENA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. Br J Haematol 71:377–386
Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR, Holland JF (1984) Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 64:267–274
Hoelzer D, Thiel E, Löffler H, Bodenstein H, Plaumann L, Büchner T, Urbanitz D, Koch P, Heimpel H, Engelhardt R, Müller U, Wendt FC, Sodomann H, Rühl H, Herrmann F, Kaboth W, Dietzfelbinger H, Pralle H, Lunscken C, Hellriegel KP, Spors S, Nowrousian RM, Fischer J, Fülle H, Mitrou PS, Pfreundschuh M, Görg C, Emmerich B, Queisser W, Meyer P, Labedzki L, Essers U, König H, Mainzer K, Herrmann R, Messerer D, Zwingers T (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64:38–47
Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Rühl H, Maschmeyer G, Lipp T, Nowrousian MR, Burkert M, Gerecke D, Pralle H, Müller U, Lunscken C, Fülle H, Ho AD, Küchler R, Busch FW, Schneider W, Görg C, Emmerich B, Braumann D, Vaupel HA, Von Paleske A, Bartels H, Neiss A, Messerer D (1988) Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71:123–131
Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE, Grever MR, Boldt D, and the Southwest Oncology Group (1989) Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy. Blood 73:57–63
Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, McCredie KB, Freireich EJ (1990) Results of vincristine, doxorubicin and dexamethasone regimen in adults with standardand high-risk acute lymphocytic leukemia. J Clin Oncol 8:994–1004
Letendre L, Colgan JP, Hineman VL, Hoagland HC (1982) Treatment of adult acute lymphocytic leukemia. Mayo Clin Proc 57:426–430
Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA (1991) Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 78:2814–2822
Omura GA, Moffitt S, Vogler R, Salter MM (1980) Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 55:199–204
Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud HH, Sandlund JT, Crist WM (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682–1687
Radford Jr JE, Burns CP, Jones MP, Gingrich RD, Kemp JD, Edwards RW, McFadden DB, Dick FR, Wen BC (1989) Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol. J Clin Oncol 7:58–66
Schauer P, Arlin ZA, Mertelsmann R, Cirrincione C, Friedman A, Gee TS, Dowling M, Kempin S, Straus DJ, Koziner B, McKenzie S, Tsvi Thaler H, Dufour P, Little C, Dellaquila C, Ellis S, Clarkson B (1983) Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1:462–470
Stein RS, Flexner JM, Collins RD (1982) Effective multidrug, multimodality consolidation therapy of adult acute lymphocytic leukemia: a preliminary report. Cancer 49:846–849
Stuck A. E., Minder C. E., Frey F. J., Risk of Infectious Complications in Patients Taking Glucocorticosteroids, 10.1093/clinids/11.6.954
Taylor PRA, Reid MM, Bown N, Hamilton PJ, Proctor SJ (1992) Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood 80:1813–1817
WHO Handbook for Reporting Results of Cancer Treatment (1979) World Health Organization, Geneva, 38
Wiernick PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, Azar C, Garl S, Benson L (1993) Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen. Leukemia 7:1236–1241
Bibliographic reference
Thomas, X. ; Danaila, C. ; Bach, QK. ; Dufour, Philippe ; Christian, B. ; et. al. Sequential Induction Chemotherapy With Vincristine, Daunorubicin, Cyclophosphamide, and Prednisone in Adult Acute Lymphoblastic-leukemia. In: Annals of Hematology, Vol. 70, no. 2, p. 65-69 (1995)